- Dr. Rottman, Prof. of Clinical Microbiology at Université de Versailles St. Quentin
“…The instrument is going to open a new era in anti-infective Personalized Medicine.”
What is COVID-19?
COVID-19 is a respiratory disease caused by SARS-CoV-2, a new coronavirus discovered in 2019. The virus is thought to spread mainly from person to person through respiratory droplets produced when an infected person coughs, sneezes, or talks.
Zhou et al. showed that 27 (50%) of 54 non-survivors had secondary infections in a study of 191 patients in China.1
Among 10 studies, the prevalence of COVID-19-associated co- and secondary infection ranged from 0.6% to 45.0%.2
72% of hospitalized COVID-19 patients received antibiotics while only 8% demonstrated bacterial or fungal co-infections.3
For 2183 hospitalized COVID-19 patients over 3 studies, the overall proportion of patients who had laboratory-confirmed bacterial co-infections was 7%.4
ICU’s in 88 countries showed that although only 54% of COVID patients had suspected bacterial infections, 70% received antibiotics.5
Specific Diagnostics' Impact on AMR caused by COVID-19
The reason that it is important to identify whether patients with COVID-19 have a co-infection, and whether this would justify the need for initial empiric antibiotic treatment, is due to concerns of complications and adverse events that may occur with the routine use of antibiotics. As the statistics show, many COVID patients, whether a co-infection is confirmed, receive broad spectrum antibiotics.
The SPECIFIC REVEAL Rapid AST System produces AST results within an average of 5.5 hours directly from blood culture.6 This allows the patient’s care team to switch them to the optimal antibiotic therapy up to 2 days sooner than with traditional AST methods. This rapid de-escalation of antibiotic therapy can help prevent AMR from occurring due to overuse of unneeded antibiotics.